Retifanlimab safety in solid tumors INCAGN02385, & INCAGN02390

Omid Hamid, MD – The Angeles Clinic

This phase 1/2 study evaluated the combination therapy of retifanlimab, INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) in patients with advanced solid tumors. The study aimed to determine the optimal doses, safety, and efficacy of these monoclonal antibody combinations. Initial results showed that the doublet and triplet regimens were well tolerated, with no significant new side effects observed. Further evaluation of the optimal doses is ongoing, with a focus on first-line treatment for melanoma. Clinical trial information can be found under NCT04370704.